title: Choroidal metastasis with adenocarcinoma of the lung treated with gefitinib.
abstract: OBJECTIVE
  To report a case of bilateral regression of choroidal metastasis with adenocarcinoma of the lung treated with gefitinib.
  
  
  METHODS
  Retrospective case review of a 68-year-old woman with pulmonary adenocarcinoma with choroidal metastasis who presented with visual loss in the left eye as the initial manifestation. Her visual acuity was 6/6 in the right eye and 6/60 in the left eye before the start of gefitinib administration. Best-corrected visual acuity and spectral-domain optical coherence tomography were compared between baseline and 3 months after treatment.
  
  
  RESULTS
  Best-corrected visual acuity in the left eye had improved to 6/30 3 months after oral gefitinib. The elevated lesions of the right eye disappeared, with decrease of subretinal fluid and retinal pigment epithelial atrophy. Spectral-domain optical coherence tomography showed that subretinal fluid of the left eye was also reduced.
  
  
  CONCLUSIONS
  Oral gefitinib could be effective for regression of choroidal metastasis in patients with adenocarcinoma of the lung and provides a potential treatment option.
authors.affiliation: Department of Ophthalmology, Yokohama City University Medical Center, Yokohama, Japan. maicoo@urahp.yokohama-cu.ac.jp
authors.forename: Maiko
authors.initials: M
authors.lastname: Inoue
authors.forename: Yoichiro
authors.initials: Y
authors.lastname: Watanabe
authors.forename: Shin
authors.initials: S
authors.lastname: Yamane
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Akira
authors.initials: A
authors.lastname: Arakawa
authors.forename: Toshinori
authors.initials: T
authors.lastname: Tsukahara
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kaneko
authors.forename: Kazuaki
authors.initials: K
authors.lastname: Kadonosono
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary; D000284:Administration, Oral; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002830:Choroid Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011799:Quinazolines / Q000627:therapeutic use*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D014792:Visual Acuity
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D066246:ErbB Receptors; D000077156:Gefitinib